Abstract - 603255 Disclosed is the compound 2-(3-(cyclopropylmethyl)-2-oxo-imidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of the compound 2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof optionally in combination with a therapeutically effective amount of one of more agents selected from the group consisting of insulin glipizide glyburide amaryl nateglinide repaglinide MCC-555 MK767 L-165041 GW7282 rosiglitazone pioglitazone troglitazone PTP-112 metformin acarbose glucagon like peptide-1 exendin-4 vildagliptin lovastatin pitavastatin simvastatin pravastatin cerivastatin mevastatin velostatin fluvastatin dalvastatin atorvastatin rosuvastatin fluindostatin rivastatin cholestyramine nicotinic acid and aspirin wherein said composition is for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) such as metabolic syndrome Syndrome X diabetes insulin resistance decreased glucose tolerance noninsulin-dependent diabetes mellitus Type II diabetes Type I diabetes a diabetic complication a body weight disorder weight loss a body mass index or leptin related disease cachexia anorexia eczema acne psoriasis keloid scar formation dyslipidemia obesity hypertension microalbuminemia hyperuricaemia or hypercoagulability.

暂无附图